MBZUAI's Eduardo da Veiga Beltrame is developing machine learning tools for analyzing single-cell RNA sequencing data, which measures RNA in thousands of individual cells. Sequencing costs have decreased faster than Moore's Law, enabling large-scale data collection in biology. RNA sequencing provides insights into gene expression and cellular activity, crucial for personalized medicine. Why it matters: Advancements in single-cell RNA sequencing and ML analysis will accelerate personalized medicine by providing detailed insights into cellular mechanisms and disease pathways.
Eduardo da Veiga Beltrame, bioinformatics lead at ImYoo (a Caltech spinout), presented on scalable methods for single-cell omics data analysis, including kallisto|bustools and scvi-tools. He highlighted their use in ImYoo's decentralized longitudinal study on Inflammatory Bowel Disease (IBD), where patients self-collect capillary blood samples. Beltrame also discussed his research on STEM education programs in Brazil as a visiting scholar at UC Berkeley. Why it matters: This highlights the growing trend of decentralized clinical studies leveraging advanced single-cell technologies for precision medicine, showcasing the potential of remote data collection and analysis in understanding complex diseases.
The Russian Immune Diversity Atlas project aims to profile immune cells from people of different ancestries at a multiomics level. The goal is to reconstruct a reference atlas of the healthy immune system and investigate its perturbations in Type II Diabetes (T2D). The project seeks to identify novel mechanisms and genetic/epigenetic markers for early T2D diagnostics, prognosis, and therapy as part of the international Human Cell Atlas. Why it matters: Addressing genetic diversity in biomedical research, particularly in the context of the Human Cell Atlas, is crucial for personalized medicine and ensuring that treatments are effective across diverse populations in the Middle East and globally.
A talk discusses the challenges of single-cell data analysis, such as feature sparsity and the effects of rare cells. AI/ML strategies are uniquely positioned to model this data. ImYoo, a startup founded in 2021, is applying single-cell model architectures for unsupervised discovery of patient groupings and predicting sample-level phenotypical data in autoimmune disease. Why it matters: This highlights the growing application of AI/ML in analyzing single-cell data for population-scale human health studies, an area ripe for innovation and improvement in the Middle East's growing biotech sector.
Natasa Przulj at the Barcelona Supercomputing Center is developing an AI framework that fuses multi-omic data to improve precision medicine. The framework uses graph-regularized non-negative matrix tri-factorization (NMTF) and network science algorithms for patient stratification, biomarker prediction, and drug repurposing. It is applied to diseases like cancer, Covid-19, and Parkinson's. Why it matters: This research can enable more personalized and effective treatments by leveraging complex biological data to understand disease mechanisms and tailor therapies.
KAUST and Oxford Nanopore Technologies have signed an MoU to collaborate on multi-omics research, building on previous work such as the NanoRanger technique developed by KAUST's Mo Li. KAUST will gain early access to Oxford Nanopore’s sequencing technology, while Oxford Nanopore will access KAUST's Core Labs. Why it matters: This partnership enhances KAUST's research capabilities in areas like rare diseases and desert agriculture, and provides Oxford Nanopore with a launchpad to engage with Saudi Arabia's research community.
MBZUAI hosted a Single Cell Summer Workshop, gathering over 25 participants and speakers to explore single-cell omics data. The two-day event featured three workshops, nine talks, and networking opportunities, aiming to develop bioinformatics skills and strengthen the regional ecosystem. Workshops were led by Eduardo Beltrame (MBZUAI), Mariano Gabitto (Allen Institute), and Luke Zappia (Data Intuitive), covering topics like scvi-tools, multimodal machine learning, and benchmarking. Why it matters: This workshop signifies MBZUAI's commitment to advancing bioinformatics research in the UAE and fostering collaboration within the regional scientific community.
MBZUAI's Assistant Professor of Computational Biology, Eduardo Beltrame, is researching single-cell RNA sequencing to advance personalized medicine. He is also designing MBZUAI’s new master’s and Ph.D. programs in computational biology, set to launch in 2026, under the guidance of Professor Eran Segal. MBZUAI's research agenda includes foundational initiatives like AIDO and the Human Phenotype Project, leveraging vast datasets such as the Emirati Genome Project. Why it matters: This highlights MBZUAI's commitment to cutting-edge research and education in computational biology, positioning it as a potential rival to top global institutions in the field.